308 related articles for article (PubMed ID: 35681627)
21. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
[TBL] [Abstract][Full Text] [Related]
22. PD-1, a follicular T-cell marker useful for recognizing nodular lymphocyte-predominant Hodgkin lymphoma.
Nam-Cha SH; Roncador G; Sanchez-Verde L; Montes-Moreno S; Acevedo A; DomÃnguez-Franjo P; Piris MA
Am J Surg Pathol; 2008 Aug; 32(8):1252-7. PubMed ID: 18594468
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells.
Sakakibara A; Kohno K; Eladl AE; Klaisuwan T; Ishikawa E; Suzuki Y; Shimada S; Nakaguro M; Shimoyama Y; Takahara T; Kato S; Asano N; Nakamura S; Satou A
Histopathology; 2018 Jun; 72(7):1156-1163. PubMed ID: 29380399
[TBL] [Abstract][Full Text] [Related]
24. The spectrum of nodular lymphocyte predominant Hodgkin lymphoma: a report of the lymphoma workshop of the 20th meeting of the European Association for Haematopathology.
Hartmann S; Dojcinov S; Dotlic S; Gibson SE; Hsi ED; Klapper W; Klimkowska M; Pinilla SMR; Richter J; Sabattini E; Tousseyn T; de Jong D
Virchows Arch; 2023 Oct; 483(4):451-463. PubMed ID: 37530790
[TBL] [Abstract][Full Text] [Related]
25. Pitfalls in the Diagnosis of Nodular Lymphocyte Predominant Hodgkin Lymphoma: Variant Patterns, Borderlines and Mimics.
Younes S; Rojansky RB; Menke JR; Gratzinger D; Natkunam Y
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34208705
[TBL] [Abstract][Full Text] [Related]
26. [Pathological diagnosis of Hodgkin lymphoma].
Tamaru J
Nihon Rinsho; 2014 Mar; 72(3):450-5. PubMed ID: 24724402
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic Utility of Flow Cytometry Analysis of Reactive T Cells in Nodular Lymphocyte-Predominant Hodgkin Lymphoma.
David JA; Huang JZ
Am J Clin Pathol; 2016 Jan; 145(1):107-15. PubMed ID: 26712878
[TBL] [Abstract][Full Text] [Related]
28. Coexisting and clonally identical classic hodgkin lymphoma and nodular lymphocyte predominant hodgkin lymphoma.
Song JY; Eberle FC; Xi L; Raffeld M; Rahma O; Wilson WH; Dunleavy K; Pittaluga S; Jaffe ES
Am J Surg Pathol; 2011 May; 35(5):767-72. PubMed ID: 21490448
[TBL] [Abstract][Full Text] [Related]
29. Single-cell profiling reveals the importance of CXCL13/CXCR5 axis biology in lymphocyte-rich classic Hodgkin lymphoma.
Aoki T; Chong LC; Takata K; Milne K; Marshall A; Chavez EA; Miyata-Takata T; Ben-Neriah S; Unrau D; Telenius A; Boyle M; Weng AP; Savage KJ; Scott DW; Farinha P; Shah SP; Nelson BH; Steidl C
Proc Natl Acad Sci U S A; 2021 Oct; 118(41):. PubMed ID: 34615710
[TBL] [Abstract][Full Text] [Related]
30. Hodgkin Lymphoma: Biology and Differential Diagnostic Problem.
Takahara T; Satou A; Tsuzuki T; Nakamura S
Diagnostics (Basel); 2022 Jun; 12(6):. PubMed ID: 35741318
[TBL] [Abstract][Full Text] [Related]
31. PD-1 and PD-L1 Immunohistochemistry as a Diagnostic Tool for Classic Hodgkin Lymphoma in Small-volume Biopsies.
Volaric A; Bacchi CE; Gru AA
Am J Surg Pathol; 2020 Oct; 44(10):1353-1366. PubMed ID: 32649320
[TBL] [Abstract][Full Text] [Related]
32. The Grey Zones of Classic Hodgkin Lymphoma.
Bosch-Schips J; Granai M; Quintanilla-Martinez L; Fend F
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35159009
[TBL] [Abstract][Full Text] [Related]
33. CD20-Negative Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A 20-Year Consecutive Case Series From a Tertiary Cancer Center.
Menke JR; Spinner MA; Natkunam Y; Warnke RA; Advani RH; Gratzinger DA
Arch Pathol Lab Med; 2021 Jun; 145(6):753-758. PubMed ID: 32991677
[TBL] [Abstract][Full Text] [Related]
34. How immunologic and genetic biomarkers impact Hodgkin lymphoma classification, diagnosis, and management: a huge potential that yet needs to be exploited.
Carbone A; Gloghini A
Int J Biol Markers; 2018 May; 33(2):137-140. PubMed ID: 29099538
[TBL] [Abstract][Full Text] [Related]
35. AP1-dependent galectin-1 expression delineates classical hodgkin and anaplastic large cell lymphomas from other lymphoid malignancies with shared molecular features.
Rodig SJ; Ouyang J; Juszczynski P; Currie T; Law K; Neuberg DS; Rabinovich GA; Shipp MA; Kutok JL
Clin Cancer Res; 2008 Jun; 14(11):3338-44. PubMed ID: 18519761
[TBL] [Abstract][Full Text] [Related]
36. Nodular Lymphocyte Predominant Hodgkin Lymphoma versus T-Cell/Histiocyte-Rich Large B-Cell Lymphoma: A Diagnostic Challenge.
Rets AV; Gottesman SR
Case Rep Pathol; 2014; 2014():956217. PubMed ID: 25110597
[TBL] [Abstract][Full Text] [Related]
37. Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte-predominant and classic Hodgkin lymphoma.
Liso A; Capello D; Marafioti T; Tiacci E; Cerri M; Distler V; Paulli M; Carbone A; Delsol G; Campo E; Pileri S; Pasqualucci L; Gaidano G; Falini B
Blood; 2006 Aug; 108(3):1013-20. PubMed ID: 16614247
[TBL] [Abstract][Full Text] [Related]
38. Characteristics and outcomes of patients with nodular lymphocyte-predominant Hodgkin lymphoma versus those with classical Hodgkin lymphoma: a population-based analysis.
Gerber NK; Atoria CL; Elkin EB; Yahalom J
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):76-83. PubMed ID: 25863756
[TBL] [Abstract][Full Text] [Related]
39. [Differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma].
Liu YH; Zhuang HG; Lin HL; Wu QL; Luo DL; Li L; Luo XL
Zhonghua Zhong Liu Za Zhi; 2006 Aug; 28(8):594-8. PubMed ID: 17243292
[TBL] [Abstract][Full Text] [Related]
40. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies.
Chen BJ; Chapuy B; Ouyang J; Sun HH; Roemer MG; Xu ML; Yu H; Fletcher CD; Freeman GJ; Shipp MA; Rodig SJ
Clin Cancer Res; 2013 Jul; 19(13):3462-73. PubMed ID: 23674495
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
